Short answer
Candel Therapeutics, Inc. (CADL) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$9M
- −220.1% YoY
- EPS (diluted)
- −$0.14
- −207.7% YoY
Source: XBRL data from the Candel Therapeutics, Inc. (CADL) Q1 2026 10-Q on SEC EDGAR. USD.
Candel Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Best and worst performing product lines not disclosed; PDAC development paused in October 2025
- 2026 follow-on offering generated approximately $93.5M net proceeds from approximately $100M gross proceeds
- Planned milestones: NSCLC phase 3 in Q2 2026, prostate BLA submission in Q4 2026, linoserpaturev mature data in Q4 2026
Risk Factors
- No material-change comparison provided; filing identifies $194.8M cash and cash equivalents as of March 31, 2026
- Trinity loan facility up to $130.0M, with $50.0M outstanding and covenant breaches potentially accelerating indebtedness
- No products approved or product-sales revenue, leaving commercialization dependent on future clinical and regulatory approvals
- Clinical-trial enrollment, retention, and execution remain key near-term operational risks for viral immunotherapy programs
- Existing cash expected to fund current operating plan into first quarter 2028, but continued losses require substantial additional financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Candel Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.